Neil Kramer, MD
Cardiovascular Disease · Scottsdale, AZNPI 1316918535
Payments from drug & device makers
Across 122 payments — averaging $21.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$479
- Sanofi-aventis U.S. LLC$413
- Novartis$393
- Merck$339
- Johnson & Johnson$142
- Astellas Pharma US Inc$135
- plus $764 from 17 others
What the payments were for
- Speaking & faculty fees$35013%
- Food & beverage$2,20483%
- Education$1124%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 22 | $479 |
| Sanofi-aventis U.S. LLC | 5 | $413 |
| Novartis | 24 | $393 |
| Merck | 18 | $339 |
| Johnson & Johnson | 9 | $142 |
| Astellas Pharma US Inc | 3 | $135 |
| Boston Scientific | 7 | $122 |
| Actelion Pharmaceuticals US, Inc. | 4 | $94 |
| Amgen | 4 | $87 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $77 |
| Heartflow, Inc. | 1 | $48 |
| Abbott | 2 | $46 |
| Gilead | 3 | $39 |
| E.r. Squibb & Sons, L.L.C. | 3 | $39 |
| Edwards Lifesciences | 1 | $37 |
| Impulse Dynamics (USA) Inc. | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 2 | $33 |
| AstraZeneca | 2 | $24 |
| EKOS Corporation | 1 | $22 |
| Medtronic | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,666 in reported general payments places this provider in the 45th percentile of 423 cardiovascular disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Scottsdale
- David RizikScottsdale$2.1M
- Krishnaswami VijayaraghavanScottsdale$927K
- Steven LesterScottsdale$336K
- William FreemanScottsdale$279K
- Paul UnderwoodScottsdale$259K
- Robert BurkeScottsdale$258K
- Imad KhaledScottsdale$252K
- Said AlsidawiScottsdale$222K
- Tasneem NaqviScottsdale$150K
- Philip GideonScottsdale$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.